Cargando…
Complete Response for More than 4 Years following Neoadjuvant FOLFOX and Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Patient with Advanced Gastric Cancer with Extensive Peritoneal Carcinomatosis
BACKGROUND: Peritoneal carcinomatosis is usually a terminal disease with short median survival in patients with gastric cancer. Systemic FOLFOX is one of the most used regimens in the first-line treatment of metastatic gastric cancer. However, there is scarce evidence that cytoreductive surgery (CRS...
Autores principales: | Peixoto, Renata D'Alpino, de Sousa, Tercia Tarciane, Silva, Pedro Alexandre Ismael Amaral, de Meirelles, Luciana Rodrigues, Teixeira, Carlos Henrique Andrade |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006599/ https://www.ncbi.nlm.nih.gov/pubmed/29928208 http://dx.doi.org/10.1159/000488978 |
Ejemplares similares
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
por: Piso, Pompiliu, et al.
Publicado: (2004) -
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis
por: Ellison, Lynne M., et al.
Publicado: (2017) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis
por: Roh, Seung Jae, et al.
Publicado: (2020) -
The Impact of Multidisciplinary Team Approach on Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
por: Hung, Hao-Chien, et al.
Publicado: (2021) -
Clinical course for patients with peritoneal carcinomatosis excluded from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Rodt, Anne Peen, et al.
Publicado: (2013)